Prix Qyuns Therapeutics Co Ltd (02509.HK)

Qyuns Therapeutics Co., Ltd. is a clinical biopharmaceutical company focusing on biotherapeutics for autoimmune and allergic diseases. The company is headquartered in Taizhou, Jiangsu and currently employs 337 full-time employees. The company went IPO on 2024-03-20. The firm is mainly engaged in biotechnology research and development of biological therapies for autoimmune and allergic diseases. The firm's business mainly covers four major disease areas, including skin, rheumatism, respiratory and digestive tract diseases. The firm is developing eight projects, with target indications including psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and asthma. The firm's core products include QX002N and QX005N.